Table 1.

Baseline characteristics in patients in AMBER by baseline eGFR subgroup and treatment

CharacteristiceGFR 25 to <30 SubgroupeGFR 30–45 Subgroup
Spironolactone + Placebo, n=34Spironolactone + Patiromer, n=32Treatment Groups Combined, n=66Spironolactone + Placebo, n=114Spironolactone + Patiromer, n=115Treatment Groups Combined, n=229
Age, mean (SD), yr68.9 (13.4)65.1 (13.8)67.1 (13.6)68.4 (10.4)68.5 (11.8)68.5 (11.1)
 ≥65, n (%)22 (64.7)18 (56.3)40 (60.6)82 (71.9)80 (69.6)162 (70.7)
White race, n (%)34 (100)32 (100)66 (100)111 (97.4)113 (98.3)224 (97.8)
Men, n (%)16 (47.1)19 (59.4)35 (53.0)61 (53.5)57 (49.6)118 (51.5)
Systolic AOBP, mean (SD), mm Hg144.0 (6.8)143.4 (6.7)143.7 (6.7)145.2 (7.1)143.3 (6.5)144.2 (6.8)
sK+, mean (SD), mEq/L4.70 (0.40)4.86 (0.35)4.78 (0.38)4.69 (0.37)4.70 (0.36)4.70 (0.36)
History of hyperkalemia, n (%)4 (11.8)3 (9.4)7 (10.6)8 (7.0)7 (6.1)15 (6.6)
Diabetes mellitus, n (%)12 (35.3)14 (43.8)26 (39.4)60 (52.6)59 (51.3)119 (52.0)
eGFR, mean (SD), ml/min per 1.73 m226.0 (3.1)26.4 (2.8)26.2 (3.0)39.1 (5.7)37.9 (6.0)38.5 (5.9)
Serum creatinine, median (Q1, Q3), mg/dl2.2 (1.9, 2.4)2.3 (1.8, 2.6)2.2 (1.8, 2.5)1.6 (1.4, 1.8)1.6 (1.4, 1.9)1.6 (1.4, 1.8)
24-h urine albumin-creatinine ratio, median (Q1, Q3), mg/g108 (37, 906)304 (37, 1308)199 (37, 1092)72 (14, 314)60 (14, 389)70 (14, 364)
24-h adjusted urine sodium, median (Q1, Q3), mEq/L per 24 h175 (115, 224)146 (102, 205)160 (105, 222)193 (144, 238)183 (131, 264)187 (138, 249)
History of heart failure, n (%)15 (44.1)14 (43.8)29 (43.9)54 (47.4)49 (42.6)103 (45.0)
History of atrial fibrillation, n (%)5 (14.7)3 (9.4)8 (12.1)12 (10.5)8 (7.0)20 (8.7)
No. of antihypertensive medications, mean (SD)3.7 (0.84)3.8 (0.91)3.7 (0.87)3.6 (0.69)3.7 (0.88)3.6 (0.79)
Use of medications for diabetes, n (%)9 (26.5)13 (40.6)22 (33.3)59 (51.8)56 (48.7)115 (50.2)
  • AOBP, automated office BP; sK+, serum potassium; Q, quartile.